Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Parabilis Medicines, Inc. (Nasdaq: PBLS), a clinical-stage biopharmaceutical company focused on developing innovative therapies for historically challenging protein targets, has successfully closed its upsized initial public offering (IPO) on June 11, 2026. The offering consisted of 38,525,000 shares of common stock priced at $20.00 per share, generating gross proceeds of approximately $770.5 million. The IPO included the full exercise of the underwriters' option to purchase an additional 5,025,000 shares. In conjunction with the IPO, Parabilis also completed a private placement of 4,166,666 shares at $18.00 per share to Regeneron Pharmaceuticals, Inc., bringing the total gross proceeds from both transactions to over $845 million.

Founded to address unmet medical needs, Parabilis Medicines has developed a proprietary platform that enables the creation of Helicons™, a novel class of stabilized helical peptides designed to target and modulate proteins that have historically been considered undruggable. The company aims to leverage this technology to create transformative therapies for patients suffering from serious diseases. The successful IPO not only enhances Parabilis' financial position but also underscores investor confidence in its innovative approach to drug development.

The biopharmaceutical sector has witnessed increased activity in IPOs as companies seek to capitalize on favorable market conditions and investor appetite for innovative healthcare solutions. Parabilis' IPO is indicative of a broader trend where clinical-stage firms are turning to public markets to fund research and development efforts. The significant capital raised through this IPO will enable Parabilis to advance its clinical programs and expand its pipeline, positioning the company for potential future growth.

The concurrent private placement with Regeneron Pharmaceuticals, a leading biotechnology company known for its focus on developing medicines for serious diseases, further validates Parabilis' strategic vision and technological capabilities. Regeneron's investment not only provides additional funding but also suggests a potential alignment in therapeutic goals, which could foster future collaborations or partnerships in drug development.

Overall, the successful IPO and private placement signal a positive outlook for Parabilis Medicines and the biopharmaceutical sector as a whole. With over $1.2 billion raised in funding throughout 2026, the company is well-positioned to pursue its mission of developing groundbreaking therapies. As the market continues to evolve, the ability of biopharmaceutical firms to attract investment will be crucial in driving innovation and addressing the pressing healthcare challenges of today.